CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10168 |
|---|---|
| Brand Name | Keytruda |
| Generic Name | Pembrolizumab |
| Strength | 25 mg / mL and 50 mg / vial |
| Tumour Type | Skin & Melanoma |
| Indication | Melanoma Adjuvant Treatment |
| Funding Request | For adjuvant treatment of Stage III melanoma patients following resection ; for re-treatment of patients upon loco-regional or distant recurrence more than 6 months following completed adjuvant course of KEYTRUDA® |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | Yes |
| NOC Date | April 2, 2019 |
| Manufacturer | Merck Canada |
| Sponsor | Merck Canada |
| Submission Date | December 13, 2018 |
| Submission Deemed Complete | January 15, 2019 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | January 4, 2019 |
| Check-point meeting | February 26, 2019 |
| pERC Meeting | May 16, 2019 |
| Initial Recommendation Issued | May 31, 2019 |
| Feedback Deadline ‡ | June 14, 2019 |
| pERC Reconsideration Meeting | July 18, 2019 |
| Final Recommendation Issued | August 1, 2019 |
| Notification to Implement Issued | August 19, 2019 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
